Evidence map›Paper›PMID 21765457›Full record

ReviewNature reviews. Genetics2011

Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation.

Anton Wutz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 362 citations in OpenAlex.

  1. Article
  2. A modified CRISPR/Cas9 approach in silencing the triplication in Down syndrome: A treatment path XISTs.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Xist in X chromosome inactivation: mechanisms and disease relevance.Cell communication and signaling : CCS · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Anton WutzWellcome Trust Centre for Stem Cell Research, Cambridge, UK. aw512@cam.ac.uk
Wellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council G0800784Wellcome Trust 087530Wellcome Trust 087530/Z/08/A
6 · The paper itself

Abstract

In female mammals, one of the two X chromosomes is silenced for dosage compensation between the sexes. X-chromosome inactivation is initiated in early embryogenesis by the Xist RNA that localizes to the inactive X chromosome. During development, the inactive X chromosome is further modified, a specialized form of facultative heterochromatin is formed and gene repression becomes stable and independent of Xist in somatic cells. The recent identification of several factors involved in this process has provided insights into the mechanism of Xist localization and gene silencing. The emerging picture is complex and suggests that chromosome-wide silencing can be partitioned into several steps, the molecular components of which are starting to be defined.

Indexed as

Gene SilencingX Chromosome InactivationAnimalsChromatin Assembly and DisassemblyDosage Compensation, GeneticEmbryonic DevelopmentFemaleHeterochromatinHumansRNA, Long NoncodingRNA, UntranslatedSequence Analysis, RNAX ChromosomeHeterochromatinRNA, Long NoncodingRNA, UntranslatedXIST non-coding RNA

Identifiers

PMID21765457
OpenAlexW2050794883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.